| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/04/2001 | CA2404428A1 High specificity marker detection |
| 10/04/2001 | CA2404411A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 10/04/2001 | CA2404233A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 10/04/2001 | CA2404157A1 Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death |
| 10/04/2001 | CA2404060A1 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation |
| 10/04/2001 | CA2404049A1 Treatment of movement disorders |
| 10/04/2001 | CA2403909A1 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 10/04/2001 | CA2403814A1 Polyamine analogues as cytotoxic agents |
| 10/04/2001 | CA2403800A1 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 10/04/2001 | CA2403637A1 Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 10/04/2001 | CA2402735A1 Human transcription factors |
| 10/04/2001 | CA2402453A1 Compounds for targeting |
| 10/04/2001 | CA2402439A1 Methods of modulating drug clearance mechanisms by altering sxr activity |
| 10/04/2001 | CA2399875A1 Crystal structure of the (aml1 runt domain) / (cbfbeta) heterodimer and the ternary complex with dna |
| 10/04/2001 | CA2374911A1 G-protein coupled receptors |
| 10/03/2001 | CN1315965A Hepatitis C inhibitor peptides |
| 10/03/2001 | CN1315873A Prevention/remedies for multiple organ failure |
| 10/03/2001 | CN1315866A Method of modulating memory effector T-cells using CD2-binding agent, and compositions |
| 10/03/2001 | CN1315863A Use of rosmarinic acid and derivatives thereof as immunosuppressant or inhibitor of SHz-mediated process |
| 10/03/2001 | CN1315856A Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| 10/03/2001 | CN1315830A Treatment of anxiety disorders |
| 10/02/2001 | US6297359 Polypeptide for use in the treatment of diabetes, dietetics, hypertension and premature atherosclerosis |
| 10/02/2001 | US6297281 Association of no syntase inhibitors with trappers of oxygen reactive forms |
| 10/02/2001 | US6297273 Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
| 10/02/2001 | US6297266 Inhibit the binding of adhesive proteins to the surface of different types of cell and accordingly influence cell-cell and cell-matrix interactions. |
| 10/02/2001 | US6297260 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 10/02/2001 | US6297243 Methods of treating hot flashes, estrogen deficiencies and deferring menopause by the administration of a luteinizing hormone antagonist |
| 10/02/2001 | US6297240 Particularly diseases caused by elevated intro-ocular pressure, such as ocular hypertension and glaucoma |
| 10/02/2001 | US6297233 Lactam inhibitors of FXa and method |
| 10/02/2001 | US6297223 Administering 5-substituted- or 5,6-dihydro-5-substituted-uracil derivative or a prodrug thereof; in conjunction with 5-fluorouracil or pro-drug thereof. |
| 10/02/2001 | US6297222 Treating or preventing radiation, mutagen and sunlight-induced biological damage, and methods for improving wound healing and tissue repair |
| 10/02/2001 | US6297220 Recombinant adenovirus comprising a dna sequence that codes for a gene product is delivered to a cardiac or vascular smooth muscle cell and the cell is maintained until that gene product is expressed. |
| 10/02/2001 | US6297022 Method of identifying agonists and antagonists for tumor necrosis related receptor TR1 |
| 10/02/2001 | US6297011 Mammalian tolloid-like gene and protein |
| 10/02/2001 | US6297003 Methods for the detection of a novel hepatitis C virus (HCV) terminal 3′ noncoding region |
| 10/02/2001 | US6296880 To cleanse skin and facilitate the prevention, treatment, and management of skin conditions |
| 10/02/2001 | US6296861 Topically applying combination of conjugated linoleic acid and fatty acid esters of ascorbic acid to treat skin damage, such as contact dermatitis, atopic dermatitis, xerosis, eczema, rosacea, seborrhea, psoriasis, thermal and radiation burns |
| 10/02/2001 | US6296853 For therapy of animal having a papilloma viral infection |
| 10/02/2001 | US6296851 For screening antibiotics |
| 09/27/2001 | WO2001071358A1 Method of screening for inhibitors of osteopontin |
| 09/27/2001 | WO2001071346A2 Binding compounds for cc chemokine receptor 5 and methods for identifying them |
| 09/27/2001 | WO2001071343A1 Methods for screening and identifying pathogen virulence factors |
| 09/27/2001 | WO2001071342A2 Identification of mast cell/basophil activation inhibitors |
| 09/27/2001 | WO2001071309A2 Methods and reagents for regulation of cellular responses in biological systems |
| 09/27/2001 | WO2001071029A1 Diagnosis of a person's risk of developing alcoholism |
| 09/27/2001 | WO2001071004A2 Proteases |
| 09/27/2001 | WO2001070975A1 Novel melanin concentrating hormone receptor |
| 09/27/2001 | WO2001070955A2 Identification of essential genes in prokaryotes |
| 09/27/2001 | WO2001070953A2 Identification of modulators of the inteferon gamma signaling pathway and their use in restenosis treatment |
| 09/27/2001 | WO2001070941A2 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| 09/27/2001 | WO2001070808A2 Angiogenesis - associated proteins, and nucleic acids encoding the same |
| 09/27/2001 | WO2001070807A2 G-protein associated molecules |
| 09/27/2001 | WO2001070776A2 Nimr compositions and their methods of use |
| 09/27/2001 | WO2001070775A2 Wnt-1 related polypeptides, and nucleic acids encoding the same |
| 09/27/2001 | WO2001070771A2 Acute neuronal induced calcium binding protein type 1 ligand |
| 09/27/2001 | WO2001070768A2 Receptor-binding compounds and method for identifying them |
| 09/27/2001 | WO2001070765A1 Receptor-binding compounds and methods for identifying them |
| 09/27/2001 | WO2001070757A2 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 09/27/2001 | WO2001070754A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | WO2001070753A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | WO2001070745A1 Pyranoindoles for treating glaucoma |
| 09/27/2001 | WO2001070738A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 09/27/2001 | WO2001070708A1 Substituted piperidines as melanocortin receptor agonists |
| 09/27/2001 | WO2001070591A1 Infusion packet with useful and decorative elements, support member, delivery system and method |
| 09/27/2001 | WO2001070337A1 Spiropiperidine derivatives as melanocortin receptor agonists |
| 09/27/2001 | WO2001070320A1 Methods and systems for enhancing fluid flow through an obstructed vascular site |
| 09/27/2001 | WO2001070273A1 The use of anticoagulant agents in the extracorporeal treatment of blood |
| 09/27/2001 | WO2001070268A1 Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
| 09/27/2001 | WO2001070266A2 Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
| 09/27/2001 | WO2001070261A1 Sperm factor oscillogenin |
| 09/27/2001 | WO2001070255A2 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 09/27/2001 | WO2001070254A1 Use of human not1 and not1a orphan receptors |
| 09/27/2001 | WO2001070248A1 Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress |
| 09/27/2001 | WO2001070231A2 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries |
| 09/27/2001 | WO2001070230A2 Compounds with 5-ht activity useful for controlling visual field loss |
| 09/27/2001 | WO2001070228A1 Antagonists of gonadotropin releasing hormone |
| 09/27/2001 | WO2001070227A1 Antagonists of gonadotropin releasing hormone |
| 09/27/2001 | WO2001070223A1 Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma |
| 09/27/2001 | WO2001070222A2 Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
| 09/27/2001 | WO2001070219A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 09/27/2001 | WO2001070216A2 Diphenyl ketoaldehyde derivatives with anti-hiv activity |
| 09/27/2001 | WO2001070215A1 Bactericidal preparation |
| 09/27/2001 | WO2001070211A2 L-arginine and phosphodiesterase (pde) inhibitor synergism |
| 09/27/2001 | WO2001070210A2 Methods for improving size and appearance of a wound |
| 09/27/2001 | WO2001070206A2 Combination of lecithin with ascorbic acid |
| 09/27/2001 | WO2001070205A2 Composition comprising paracetamol and niflumic acid |
| 09/27/2001 | WO2001070200A1 Pharmaceutical composition for administration to mucosal surfaces |
| 09/27/2001 | WO2001070176A2 Use of 3,4-dihydroxy-mandelic acid for protecting against oxidative damage caused by ultra-violet light |
| 09/27/2001 | WO2001070174A2 Vegf-modulated genes and methods employing them |
| 09/27/2001 | WO2001070046A1 Natural vegetable oil concentrated in unsaponifiable matters as food ingredient |
| 09/27/2001 | WO2001062234A8 Dosing regimen |
| 09/27/2001 | WO2001025390A3 Water unstable foam compositions |
| 09/27/2001 | WO2001019973A3 Nicotinic acetylcholine receptor: alpha10 subunit |
| 09/27/2001 | WO2001019357A3 Combination preparation for the treatment of sexual dysfunction |
| 09/27/2001 | WO2001019320A3 Phospholipid prodrugs of anti-proliferative drugs |
| 09/27/2001 | WO2001018546A3 Screening for inhibitors of 'paired helical filaments' |
| 09/27/2001 | WO2001017558A3 Novel uses of mammalian ccr6 receptors and related reagents |
| 09/27/2001 | WO2001016170A3 Card proteins involved in cell death regulation |
| 09/27/2001 | WO2001015684A3 Antimycotic drug |
| 09/27/2001 | WO2001010903A3 Proteases and protease inhibitors |